

November 5, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2025.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2025.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500038, Telangana, India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721211
Email: ir@aurobindo.com

Hyderabad, India, November 05th, 2025: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUOPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended September 30, 2025.

Aurobindo Pharma Limited Q2FY26

Amount (INR Cr)	Q2 FY26	Q2 FY25	%Change YoY	Q1 FY26	%Change QoQ
Revenue from Operations	8,286	7,796	6.3%	7,868	5.3%
EBITDA before R&D	2,064	1,954	5.7%	1,947	6.0%
EBITDA margin before R&D	24.9%	25.1%	-15 bps	24.8%	16 bps
EBITDA before Forex and Other Income	1,678	1,566	7.1%	1,603	4.7%
EBITDA Margin (%)	20.3%	20.1%	16 bps	20.4%	-13 bps
PBT before share of P/L of JV, Forex, and Exceptional items	1,274	1,207	5.6%	1,205	5.8%
Net Profit for the period	848	817	3.8%	824	2.9%

Key Highlights of Q2FY26

- Revenue from Operations increased by 6.3% YoY to INR 8,286 Cr with growth in US, Europe and Growth markets
- US formulations revenue increased by 3.1% YoY to INR 3,638 Cr (USD 417 million)
- Europe formulations revenue increased by 17.8% YoY to INR 2,480 Cr (EUR 243 million)
- Growth Markets revenue increased by 8.7% YoY to INR 882 Cr (USD 101 million)
- ARV revenue increased by 68.7% YoY to INR 325 Cr (USD 37 million)
- EBITDA before R&D stood at INR 2,064 crores with a margin of 24.9%
- EBITDA before Forex and Other Income stood at INR 1,678 Cr; EBITDA margin at 20.3%
- Research & Development (R&D including depreciation) spend was INR 414 Cr, 5.0% of revenues
- Received final approval for 7 ANDAs from the USFDA
- Net Profit for the period stood at INR 848 Cr
- Strong net cash position at USD 170mn as on 30-Sep-25
- Free Cashflows generated (before dividend and buybacks) of \$57mn during the quarter
- Basic & Diluted EPS stood at INR 14.61 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "Q2 has been another steady quarter for Aurobindo, demonstrating the resilience of our base business and the depth of our product portfolio. We continue to see healthy demand across key markets, with our U.S. and Europe businesses performing in line with expectations. The balance between growth and profitability remains central to our execution. With the momentum we've built and all strategic initiatives progressing as planned, we are confident of meeting our annual guidance and sustaining long-term value creation."



Q2FY26: Operational Performance (Consolidated)

₹ Cr	Q2FY26	Q2FY25	Y-o-Y (%)	Q1FY26	Q-o-Q (%)
USA	3,638	3,530	3.1%	3,488	4.3%
Europe	2,480	2,105	17.8%	2,338	6.1%
Growth Markets*	882	812	8.7%	772	14.3%
ARV	325	193	68.7%	355	-8.3%
Total Formulations	7,325	6,640	10.3%	6,953	5.4%
Beta-lactam	668	837	-20.1%	633	5.6%
Non Beta-lactam	292	319	-8.3%	283	3.3%
Total API	961	1,156	-16.9%	916	4.9%
Revenue from operations	8,286	7,796	6.3%	7,868	5.3%

*Includes domestic formulation sales of INR 81 Cr in Q2FY26 against INR 71 Cr in Q1 FY26

Q2FY26: Consolidated Revenue Breakup - Geography & Business Wise

Q2FY26



Q2FY26: Business Area Wise Performance

Formulations revenue increased by 10.3% YoY to INR 7,325 Cr.

US Formulations

- US revenue increased by 3.1% YoY to INR 3,638 Cr and accounted for 43.9% of consolidated revenue
- Filed 13 ANDAs with USFDA during the quarter
- Received final approval for 7 ANDAs during the quarter
- As on 30th September 2025, on a cumulative basis, the company has filed 876 ANDAs with USFDA and received 711 final approvals and 31 tentative approvals
- The company has launched 6 products during the quarter

Europe Formulations

- Europe revenue increased by 17.8% YoY to INR 2,480 Cr driven by robust performance across all key markets; and accounted for 29.9% of consolidated revenue
- In Euro terms, revenue increased by 6.3% YoY to EUR 243 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 8.7% YoY to INR 882 Cr driven by good performance in key markets; and accounted for 10.6% of consolidated revenue
- In USD terms, revenue increased by 4.4% YoY to USD 101 million
- Domestic formulation sales for the quarter stood at INR 81 Cr, H1FY26 Domestic formulations revenues stood at 152 Cr

ARV Formulations

- ARV business revenue increased by 68.7% YoY to INR 325 Cr accounting for 3.9% of consolidated revenue
- In USD terms, revenue increased by 61.9% YoY to USD 37 million

Active Pharmaceutical Ingredients (API)

- API revenues decreased by 16.9% Y-o-Y to INR 961 Cr contributing to 11.6% of consolidated revenue
- In USD terms, revenue decreased by 20.3% to USD 110 million

Q2FY26: Global Regulatory Filings

Details	Q2FY26	Cumulative Filings as on 30 th Sep 2025
US ANDAs (including filings from Aurobindo USA)	13	876
US DMFs (including filings from Eugia and Auro Peptides)	1	311
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	220	4,906
API filings in other key regulated markets (incl. multiple registrations)	28	4,058

Q2FY26: Final USFDA Approvals Received

Received by Aurobindo Pharma Limited

#	Product	Strength	Therapy Area
1	Pirfenidone Tablets (FTF)	267 mg and 801 mg	Antifibrotic agent
2	Deferasirox Oral Granules	90 mg, 180 mg and 360 mg	Iron-chelating agent
3	Prochlorperazine Maleate Tablets USP	5 mg and 10 mg	Central Nervous System
4	Furosemide Tablets USP	20 mg, 40 mg and 80 mg	Cardiovascular
5	Famotidine for oral Suspension USP	40 mg/ 5mL	Gastrointestinal
6	Metronidazole Topical Cream	0.75%	Anti-Infectives
7	Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous)	2%	Central Nervous System

Q2FY26: Earnings Call Details

The company will host earnings call at **8.30 AM IST on 6th November 2025**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <https://bit.ly/4oBFSmm>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications

Phone: 040-66721211

Email: ir@aurobindo.com